Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gerald Dal Pan

Showing results (1-10 of 38) with videos related to

Pageof 4
Sort By:
Drug Safety|May 17, 2022
"Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?Robert Ball, Gerald Dal Pan
The New England Journal of Medicine|February 26, 2010
The FDA and safe use of long-acting beta-agonists in the treatment of asthmaBadrul A Chowdhury, Gerald Dal Pan
The New England Journal of Medicine|June 7, 2018
Assessing Drug Safety in Children - The Role of Real-World DataAnn W McMahon, Gerald Dal Pan
Clinical Pharmacology and Therapeutics|August 20, 2025
Response to FDA Adverse Event Reporting System (FAERS) Essentials: A Reflection on Study ConceptionMelissa Reyes, Emeri Potter, Gerald Dal Pan
Pharmacoepidemiology and Drug Safety|January 5, 2008
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysisMara McAdams, Judy Staffa, Gerald Dal Pan
Clinical Pharmacology and Therapeutics|May 19, 2025
FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERSEmeri Potter, Melissa Reyes, Jennifer Naples, et al.
Pharmacoepidemiology and Drug Safety|October 4, 2012
Post-market drug safety evidence sources: an analysis of FDA drug safety communicationsChieko Ishiguro, Marni Hall, George A Neyarapally, et al.
American Journal of Public Health|June 18, 2026
Naloxone Distribution in the United States, 2018-2023Corinne Woods, Grace Chai, Jae Wook Yoo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2012
Reply to Ison et AlAlfred Sorbello, S Christopher Jones, Debra Birnkrant, et al.
Pharmacoepidemiology and Drug Safety|February 24, 2012
Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug AdministrationSonja Brajovic, Toni Piazza-Hepp, Lynette Swartz, et al.
Pageof 4

Showing results (1-10 of 38) with videos related to

Sort By:
Pageof 4
Drug Safety|May 17, 2022
"Artificial Intelligence" for Pharmacovigilance: Ready for Prime Time?Robert Ball, Gerald Dal Pan
The New England Journal of Medicine|February 26, 2010
The FDA and safe use of long-acting beta-agonists in the treatment of asthmaBadrul A Chowdhury, Gerald Dal Pan
The New England Journal of Medicine|June 7, 2018
Assessing Drug Safety in Children - The Role of Real-World DataAnn W McMahon, Gerald Dal Pan
Clinical Pharmacology and Therapeutics|August 20, 2025
Response to FDA Adverse Event Reporting System (FAERS) Essentials: A Reflection on Study ConceptionMelissa Reyes, Emeri Potter, Gerald Dal Pan
Pharmacoepidemiology and Drug Safety|January 5, 2008
Estimating the extent of reporting to FDA: a case study of statin-associated rhabdomyolysisMara McAdams, Judy Staffa, Gerald Dal Pan
Clinical Pharmacology and Therapeutics|May 19, 2025
FDA Adverse Event Reporting System (FAERS) Essentials: A Guide to Understanding, Applying, and Interpreting Adverse Event Data Reported to FAERSEmeri Potter, Melissa Reyes, Jennifer Naples, et al.
Pharmacoepidemiology and Drug Safety|October 4, 2012
Post-market drug safety evidence sources: an analysis of FDA drug safety communicationsChieko Ishiguro, Marni Hall, George A Neyarapally, et al.
American Journal of Public Health|June 18, 2026
Naloxone Distribution in the United States, 2018-2023Corinne Woods, Grace Chai, Jae Wook Yoo, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 14, 2012
Reply to Ison et AlAlfred Sorbello, S Christopher Jones, Debra Birnkrant, et al.
Pharmacoepidemiology and Drug Safety|February 24, 2012
Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug AdministrationSonja Brajovic, Toni Piazza-Hepp, Lynette Swartz, et al.
Pageof 4